• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Rongen Roelof

    8/14/23 4:07:02 PM ET
    $VLON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $VLON alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rongen Roelof

    (Last) (First) (Middle)
    C/O GRI BIO, INC.
    2223 AVENIDA DE LA PLAYA, SUITE 208

    (Street)
    LA JOLLA CA 92037

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GRI BIO, Inc. [ GRI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/10/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.9 08/10/2023 A 34,483 (1) 08/10/2033 Common Stock 34,483 $2.9 34,483 D
    Explanation of Responses:
    1. Vests as to 1/12th of the underlying shares of common stock on the date of grant, then in 11 equal quarterly installments such that the stock option is fully vested on the third annual anniversary of the date of grant.
    Remarks:
    /s/ Leanne Kelly, Attorney-in-Fact 08/14/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VLON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VLON

    DatePrice TargetRatingAnalyst
    11/22/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VLON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

      Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T ("NKT") modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of the combined company into mid-2024 Trading on Nasdaq under the ticker symbol "GRI" expected to commence April 24, 2023 PHILADELPHIA, PA, April 21, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:VLON), ("GRI," "GRI Bio," or the "Company"), today announced the completion of the previously announced merger between Vallon Pharmaceuticals, Inc. (now GRI Bio, Inc.) and GRI Bio, Inc. (now GRI Bio Operations, Inc. and referred to herein as "Priva

      4/21/23 11:55:00 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

      Vallon's board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) ("Vallon" or the "Company") today announced that its stockholders have approved Proposals 1, 2, 4 and 5, related to the previously announced proposed merger with GRI Bio, Inc., a privately held biotechnology company ("GRI Bio" or "GRI"), at a special meeting of stockholders held on April 20, 2023 (the "Special Meeting"). Accordingly, at the effective time of the merger, each share of GRI's common stock, will be automatically converted into the right to receive a number of shares of Vallon's common st

      4/20/23 6:45:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

      Board of Directors unanimously recommend Vallon stockholders to vote "FOR" all proposals outlined in the Company's definitive Proxy Statement (the "Proxy") in order to close the proposed merger with GRI Bio, Inc. PHILADELPHIA, PA, April 12, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), today announced that its Special Meeting of Stockholders, scheduled for and convened on April 12, 2023, has been adjourned to provide the Company's stockholders additional time to consider and vote FOR the proposals in the Proxy. Vallon intends to reconvene the Special Meeting on April 20, 2023 at 9:00 am ET. The Vallon board of directors unanimou

      4/12/23 4:05:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Vallon Pharmaceuticals Inc.

      SC 13G - GRI BIO, Inc. (0001824293) (Subject)

      5/2/23 8:23:53 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Vallon Pharmaceuticals Inc.

      SC 13G - GRI BIO, Inc. (0001824293) (Subject)

      5/2/23 4:05:32 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Vallon Pharmaceuticals Inc.

      SC 13D - GRI BIO, Inc. (0001824293) (Subject)

      4/25/23 4:19:44 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kelly Leanne

      4 - GRI BIO, Inc. (0001824293) (Issuer)

      9/26/23 4:08:55 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Szekeres David Leslie

      4 - GRI BIO, Inc. (0001824293) (Issuer)

      8/14/23 4:10:06 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Simpson Camilla V

      4 - GRI BIO, Inc. (0001824293) (Issuer)

      8/14/23 4:07:42 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Leadership Updates

    Live Leadership Updates

    See more
    • Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors

      Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies Philadelphia, PA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Meenu Karson to its Board of Directors. "We are excited to welcome Ms. Karson to our Board of Directors. Over the course of her career, she has l

      2/28/22 4:05:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

      - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the ~$9 billion US ADHD market PHILADELPHIA, PA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2021. The Company also provided an update on its development programs, ADAIR and ADMIR

      8/10/21 8:05:00 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer

      - Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e

      5/11/21 9:05:00 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Vallon Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Vallon Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      11/22/21 6:24:06 AM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care

    $VLON
    SEC Filings

    See more
    • SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.

      424B3 - GRI BIO, Inc. (0001824293) (Filer)

      2/2/24 4:25:45 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - GRI BIO, Inc. (0001824293) (Filer)

      2/2/24 4:23:00 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.

      424B4 - GRI BIO, Inc. (0001824293) (Filer)

      2/2/24 4:21:50 PM ET
      $VLON
      Medicinal Chemicals and Botanical Products
      Health Care